Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of PT886 combined with chemotherapy and/or immune checkpoint inhibitors in advanced gastrointestinal solid tumors
CTR20252758Phase 2Active
- Sponsor
- F-star
- Start
- Jul 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of spevatamig in gastric cancer (GC), esophagogastric junction cancer, pancreatic cancer (PC), biliary cancer, sponsored by F-star. Started Jul 2025; status: active.
02
Drugs
spevatamig
03
Conditions
gastric cancer (GC)esophagogastric junction cancerpancreatic cancer (PC)biliary cancer
Beyond the preview
Go deeper on CTR20252758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252758.